From maximising immune response with combination biomarkers to conducting diagnostic innovation in immunotherapy prognosis, the future of predictive biomarkers is fast approaching. We speak to senior representatives from industry and academia to find out more.

Key opinion leaders from GlaxoSmithKline and Weill Cornell Medicine discuss future perspectives on neuro-organoids.

Jordi Clarimon, Lead Specialist in Fluid Biomarkers at Lundbeck, leads a discussion on ‘Fluid Biomarkers for Neurodegenerative Diseases.

In this Commentary article, we investigate the applications of human stem cell modelling for identifying the ways in which neurodegenerative diseases such as Alzheimer's and Parkinson's affect the brain.

This Commentary article explores the applications of pathway mining for the identification of disease targets associated with breast cancer, where there is an unmet need for treatment. The mission is to identify the best proliferation marker for guiding the choice of systemic treatments for breast cancer.

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our March Discussion Group addressing ‘Translational Biomarkers to Guide Clinical Development of CAR T-Cells’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

Data management for diagnostic devices is fast becoming a vital concern of the biomarkers industry. With the increased prevalence of ML and AI, this article interviews key opinion leaders from Nottingham Trent University, Apis Assay Technologies, and UCB about the future perspectives of diagnostic innovation and regulation.

Looking at how Ultivue uses spatial imaging to observe biomarkers

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our February Discussion Group, focusing on ‘Using Biomarkers For Clinical Development & Regulatory Approval,’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

How can the industry transform itself with improved biomarkers for clinical development? And what hurdles stand in the way? We sat down with senior representatives from Galapagos, Ohio State University, and Genentech to find out more.

Melanie Anderson, Principal Scientist at MSD, on how the pandemic has made scientists rethink clinical trials.

Oxford Global’s Discussion Groups provide a focused networking opportunity for a select group of like-minded experts on a monthly basis. Our first Biomarkers Discussion Group addressing ‘Implementing Flow Cytometry Assays In Biomarker Research’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

This commentary article looks at the latest applications in digital and wearable biomarkers, with industry and academic insights from GlaxoSmithKline, Roche, and University College London.

Dr Derek Hill, Professor of Digital Health at University College London, on making the most of digital biomarkers and achieving clinical endpoints.

How do we implement the next generation of precision medicines and therapies to optimise patient experience? We sat down with senior representatives from Novartis, Merus, Labcorp, and Simcere Pharmaceuticals to discover the latest industry insights.

Liquid biopsy has the potential to become a transformative cancer management and therapeutic strategy within the next 5 to 10 years. However, its capability across all cancer stages largely depends upon assay sensitivity. In this commentary piece, the University of Edinburgh’s Tim Aitman takes us through a novel approach set to pioneer the landscape of liquid biopsy.

With an increasing need for large data analysis and validation, this Insight article takes an in-depth look at some of the recent advances in automation technologies affecting the flow cytometry field.

How can the biomarkers industry best implement multi-parameter flow cytometry in clinical drug development? Vilma Decman of GlaxoSmithKline takes us through the advantages of using spectral flow cytometry, the importance of viability dyes, and high-parameter panel design.

Qing Kang-Fortner, Ph.D., Senior Scientist, Translational Medicine, Syros Pharmaceuticals, Inc

Steve Anderson, Senior Vice President, Chief Scientific Officer, Covance